Home

The Translational Research Cancer Centers Consortium (TRCCC) mission is to gain a greater understanding of the interactions between the immune system and cancer in the setting of biologic therapy of cancer.

TRCCC News

2013 TRCCC Annual Meeting
The PowerPoint presentations regarding grant funding in difficult time and opportunities are available for download on the website.

2012 TRCCC Annual Meeting Recap

The 2012 TRCCC Annual meeting was a tremendous success, with more than 180 participants in attendance. The addition of the advocacy session, and discussion with vendors was welcomed and appreciated by all. "It was truly an amazing, well organized meeting, filled with outstanding and novel science and new initiatives. I was very impressed by the progress and ideas emerging from the advocates workshop, the energy and enthusiasm demonstrated by our graduate students and young investigators." said Elizabeth Repasky, a participant of the event. To view pictures from the event, a list of the abstract presentations, and more feed back from participants, click here. 

Roswell Park Cancer Institute Develops Cancer Vaccine
(January 24, 2012) The Center for Immunotherapy at Roswell Park Cancer Institute (RPCI), a TRCCC member, has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse. Developed at RPCI, the NY-ESO-1 dendritic cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process — making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study. Read More.